Publication:
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Issued Date

2021-02-09

Resource Type

Article

ISSN

24739537
24739529

DOI

10.1182/bloodadvances.2020003763

Other identifier(s)

2-s2.0-85101210704

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Blood Advances. Vol.5, No.3 (2021), 872-888

Suggested Citation

Adam Cuker, Eric K. Tseng, Robby Nieuwlaat, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Jennifer Davila, Maria T. DeSancho, David Diuguid, Daniel O. Griffin, Susan R. Kahn, Frederikus A. Klok, Alfred Ian Lee, Ignacio Neumann, Ashok Pai, Menaka Pai, Marc Righini, Kristen M. Sanfilippo, Deborah Siegal, Mike Skara, Kamshad Touri, Elie A. Akl, Imad Bou Akl, Mary Boulos, Romina Brignardello-Petersen, Rana Charide, Matthew Chan, Karin Dearness, Andrea J. Darzi, Philipp Kolb, Luis E. Colunga-Lozano, Razan Mansour, Gian Paolo Morgano, Rami Z. Morsi, Atefeh Noori, Thomas Piggott, Yuan Qiu, Yetiani Roldan, Finn Schünemann, Adrienne Stevens, Karla Solo, Matthew Ventresca, Wojtek Wiercioch, Reem A. Mustafa, Holger J. Schünemann American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances. Vol.5, No.3 (2021), 872-888. doi:10.1182/bloodadvances.2020003763 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78448

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Author(s)

Adam Cuker
 Eric K. Tseng
 Robby Nieuwlaat
 Pantep Angchaisuksiri
 Clifton Blair
 Kathryn Dane
 Jennifer Davila
 Maria T. DeSancho
 David Diuguid
 Daniel O. Griffin
 Susan R. Kahn
 Frederikus A. Klok
 Alfred Ian Lee
 Ignacio Neumann
 Ashok Pai
 Menaka Pai
 Marc Righini
 Kristen M. Sanfilippo
 Deborah Siegal
 Mike Skara
 Kamshad Touri
 Elie A. Akl
 Imad Bou Akl
 Mary Boulos
 Romina Brignardello-Petersen
 Rana Charide
 Matthew Chan
 Karin Dearness
 Andrea J. Darzi
 Philipp Kolb
 Luis E. Colunga-Lozano
 Razan Mansour
 Gian Paolo Morgano
 Rami Z. Morsi
 Atefeh Noori
 Thomas Piggott
 Yuan Qiu
 Yetiani Roldan
 Finn Schünemann
 Adrienne Stevens
 Karla Solo
 Matthew Ventresca
 Wojtek Wiercioch
 Reem A. Mustafa
 Holger J. Schünemann

Other Contributor(s)

Ramathibodi Hospital
 Michael G. DeGroote School of Medicine
 School of Medicine
 Albert Ludwigs Universität Freiburg, Medizinische Fakultät
 L'Hôpital d'Ottawa
 American University of Beirut
 King Hussein Cancer Center
 McMaster University
 Pontificia Universidad Católica de Chile
 The University of Chicago
 McMaster University, Faculty of Health Sciences
 Universitätsklinikum Freiburg
 Penn Medicine
 Washington University School of Medicine in St. Louis
 New York Presbyterian Hospital
 Yale School of Medicine
 Kaiser Permanente
 Saint Michael's Hospital University of Toronto
 Leids Universitair Medisch Centrum
 Vagelos College of Physicians and Surgeons
 St. Joseph's Healthcare Hamilton
 Hôpitaux Universitaires de Genève
 Universidad de Guadalajara
 University of Kansas Medical Center
 Albert Einstein College of Medicine of Yeshiva University
 Ottawa Hospital Research Institute
 The Johns Hopkins Hospital
 Research and Development
 Prohealth NY

Abstract

Background: Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE. Methods: ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE. Conclusions: These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/78448

Collections

Scopus 2021